Empagliflozin Disrupts a Tnfrsf12a-Mediated Feed Forward Loop That Promotes Left Ventricular Hypertrophy
ConclusionEmpagliflozin attenuates LV enlargement in mice with hypertrophic heart failure. This effect may be mediated, at least in part, by a reduction in loading conditions which limits upregulation of the inducible, proinflammatory, and prohypertrophic TNF superfamily receptor, Tnfrsf12a. Disruption of the Tnfsf12/Tnfrsf12a feed forward system may contribute to the cardioprotective benefits of SGLT2 inhibition.Graphical abstract
Source: Cardiovascular Drugs and Therapy - Category: Cardiology Source Type: research
More News: Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Diets | Empagliflozin | Heart | Heart Failure | Jardiance | Nutrition | SGLT2 Inhibitors | Sodium